Regencell Bioscience Holdings Ltd. (RGC) News

Regencell Bioscience Holdings Ltd. (RGC): $32.50

-0.70 (-2.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter RGC News Items

RGC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest RGC News From Around the Web

Below are the latest news stories about Regencell Bioscience Holdings Ltd that investors may wish to consider to help them evaluate RGC as an investment opportunity.

Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network

LOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with the team from Regencell Bioscience Holdings Limited (NASDAQ:RGC), including: Jay Lee, CEO of Regencell Bioscience Asia Limited, and Paul Niewiadomski, Independent Director. Regencell is an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degene

Yahoo | March 1, 2022

Regencell Bioscience's COVID-19 Candidate Shows Encouraging Action On Mild To Moderate Symptoms

Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the results from the EARTH efficacy trial of its COVID-19 candidate. RGC-COV19 (Regencell Bioscience (RGCA-CV01) liquid formulation) is an oral TCM candidate. Out of the 37 COVID-19 patients, 36 had all symptoms eliminated, save for Sensory Dysfunction & occasional cough, within the 6-day treatment period. The trial that after taking RGC-COV19TM, 97.3% of the patients had their mild to moderate COVID-19 symptoms eliminated, save for S

Yahoo | February 17, 2022

Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial

HONG KONG, February 17, 2022--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company") today announced the results from an analysis of a total of 37 individuals enrolled in its Evaluation and Assessment of RGC-COV19TM TCM through a Holistic approach ("EARTH") efficacy trial conducted by Regencell Bioscience Asia Limited ("Regencell Asia") of its novel COVID-19 oral TCM candidate RGC-COV19TM (Regencell Bioscience (RGCA-CV01) liquid formulation). The results have yet to b

Yahoo | February 17, 2022

Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors

HONG KONG, December 13, 2021--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system, announced the appointment of Dr. William Wing-Yan Lo, JP to its Board of Directors, effective immediately, to strengthen its Board of Director and fill the

Yahoo | December 13, 2021

Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO

HONG KONG, November 22, 2021--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system, announced that Yat-Gai Au, the Company’s Chairman & CEO, made Ordinary Share purchases of Regencell ("Ordinary Shares") totaling $1,125,807.

Yahoo | November 22, 2021

Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index

HONG KONG, November 22, 2021--Regencell Bioscience Holdings Limited (NASDAQ: RGC) ("Regencell" or the "Company"), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system, announced that the ordinary shares of the Company will be added to the MSCI World Micro Cap Index on November 30, 2021 after the close of market (effective

Yahoo | November 22, 2021

RGC: Traditional Chinese Medicine Approach for treatment of neurodevelopmental conditions

By Beth Senko, CFA NASDAQ:RGC Founded in 2014, Hong Kong-based Regencell Bioscience (NASDAQ:RGC) is an early clinical stage bioscience company using a traditional Chinese medicine (TCM) approach to develop standardized TCM formulas to holistically treat different elements of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in adolescents, and infectious diseases

Yahoo | November 2, 2021

Do Institutions Own Regencell Bioscience Holdings Limited (NASDAQ:RGC) Shares?

The big shareholder groups in Regencell Bioscience Holdings Limited ( NASDAQ:RGC ) have power over the company...

Yahoo | October 19, 2021

Cineworld to pay £122m to dissenting shareholders after Regal takeover

The original acquisition of Regal was a deal worth around £2.7 billion, or around 23 US dollars per share, in 2017.

Yahoo | September 10, 2021

UPDATE 1-Cineworld pays $170 mln to Regal investors unhappy with 2017 buyout

Cineworld, the world's second-largest movie theatre operator, said it will pay $170 million to Regal Entertainment shareholders, who were disgruntled with the price they received when the London-listed company took over the U.S. chain in 2017. According to an agreement, $92 million will be held in escrow and be available to Cineworld as additional liquidity under certain circumstances for the payment, Cineworld said on Friday. Cineworld included $244.2 million in its last annual report, which it said represented the amount payable to a group of Regal's former stakeholders who had challenged whether they received a fair market price for their shares.

Yahoo | September 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4941 seconds.